{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:07:56Z","timestamp":1787026076487,"version":"build-2736575974"},"reference-count":105,"publisher":"XMLink","issue":"43","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["jkms.org"],"crossmark-restriction":false},"short-container-title":["J Korean Med Sci"],"DOI":"10.3346\/jkms.2024.39.e320","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T20:33:13Z","timestamp":1729542793000},"update-policy":"https:\/\/doi.org\/10.3346\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["FGFR Inhibitors in Urothelial Cancer: From Scientific Rationale to Clinical Development"],"prefix":"10.3346","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7833-5981","authenticated-orcid":false,"given":"Whi-An","family":"Kwon","sequence":"first","affiliation":[{"name":"Department of Urology, Myongji Hospital, Hanyang University College of Medicine, Goyang, Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18617","published-online":{"date-parts":[[2024]]},"reference":[{"issue":"19","key":"10.3346\/jkms.2024.39.e320_ref1","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1001\/jama.2020.17598","volume":"324","author":"Lenis","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"10.3346\/jkms.2024.39.e320_ref2","first-page":"15","volume":"8","author":"Saginala","year":"2020","journal-title":"Med Sci (Basel)"},{"issue":"7","key":"10.3346\/jkms.2024.39.e320_ref3","first-page":"e27330","volume":"14","author":"Halaseh","year":"2022","journal-title":"Cureus"},{"issue":"2","key":"10.3346\/jkms.2024.39.e320_ref4","doi-asserted-by":"crossref","first-page":"385","DOI":"10.4143\/crt.2023.447","volume":"55","author":"Kang","year":"2023","journal-title":"Cancer Res Treat"},{"key":"10.3346\/jkms.2024.39.e320_ref5","unstructured":"International Agency for Research on Cancer. Global cancer observatory. Cancer today. Updated 2024. Accessed August 21, 2024.  https:\/\/gco.iarc.fr\/en"},{"issue":"1","key":"10.3346\/jkms.2024.39.e320_ref6","doi-asserted-by":"crossref","first-page":"32","DOI":"10.22465\/juo.234600080004","volume":"21","author":"Han","year":"2023","journal-title":"Korean J Urol Oncol"},{"issue":"1","key":"10.3346\/jkms.2024.39.e320_ref7","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","volume":"71","author":"Antoni","year":"2017","journal-title":"Eur Urol"},{"issue":"5","key":"10.3346\/jkms.2024.39.e320_ref8","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3322\/caac.21631","volume":"70","author":"Patel","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.3346\/jkms.2024.39.e320_ref9","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12935-023-02902-0","volume":"23","author":"Marei","year":"2023","journal-title":"Cancer Cell Int"},{"issue":"13","key":"10.3346\/jkms.2024.39.e320_ref10","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.3390\/cancers16132420","volume":"16","author":"Kwon","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.3346\/jkms.2024.39.e320_ref11","doi-asserted-by":"crossref","first-page":"931906","DOI":"10.3389\/fimmu.2022.931906","volume":"13","author":"Xu","year":"2022","journal-title":"Front Immunol"},{"issue":"22","key":"10.3346\/jkms.2024.39.e320_ref12","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.3390\/cancers13225681","volume":"13","author":"Chioni","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.3346\/jkms.2024.39.e320_ref13","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN gudelines for bladder cancer. Updated 2024. Accessed August 21, 2024.  https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1417"},{"issue":"10","key":"10.3346\/jkms.2024.39.e320_ref14","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.3346\/jkms.2024.39.e320_ref15","doi-asserted-by":"crossref","first-page":"218142","DOI":"10.4061\/2010\/218142","volume":"2010","author":"Yun","year":"2010","journal-title":"J Tissue Eng"},{"issue":"1","key":"10.3346\/jkms.2024.39.e320_ref16","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41392-020-00222-7","volume":"5","author":"Xie","year":"2020","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"10.3346\/jkms.2024.39.e320_ref17","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1248\/bpb.30.1819","volume":"30","author":"Itoh","year":"2007","journal-title":"Biol Pharm Bull"},{"issue":"1","key":"10.3346\/jkms.2024.39.e320_ref18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3390\/jcm8010007","volume":"8","author":"Por\u0119bska","year":"2018","journal-title":"J Clin Med"},{"issue":"5","key":"10.3346\/jkms.2024.39.e320_ref19","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41416-020-01157-0","volume":"124","author":"Krook","year":"2021","journal-title":"Br J Cancer"},{"issue":"1","key":"10.3346\/jkms.2024.39.e320_ref20","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12943-023-01761-7","volume":"22","author":"Ruan","year":"2023","journal-title":"Mol Cancer"},{"issue":"1","key":"10.3346\/jkms.2024.39.e320_ref21","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.3346\/jkms.2024.39.e320_ref22","unstructured":"American Association for Cancer Research (AACR). AACR GENIE 13.0-public data guide. Updated 2022. Accessed August 21, 2024.  https:\/\/www.aacr.org\/wp-content\/uploads\/2023\/03\/13.0_data_guide-1.pdf"},{"issue":"4","key":"10.3346\/jkms.2024.39.e320_ref23","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"issue":"7","key":"10.3346\/jkms.2024.39.e320_ref24","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.3390\/cancers14071795","volume":"14","author":"Thomas","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.3346\/jkms.2024.39.e320_ref25","doi-asserted-by":"crossref","first-page":"101208","DOI":"10.1016\/j.tranon.2021.101208","volume":"14","author":"Chang","year":"2021","journal-title":"Transl Oncol"},{"issue":"1","key":"10.3346\/jkms.2024.39.e320_ref26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13045-021-01040-2","volume":"14","author":"Yue","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.3346\/jkms.2024.39.e320_ref27","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1158\/1078-0432.CCR-23-1317","volume":"30","author":"Wu","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.3346\/jkms.2024.39.e320_ref28","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.eururo.2018.08.027","volume":"75","author":"Tan","year":"2019","journal-title":"Eur Urol"},{"key":"10.3346\/jkms.2024.39.e320_ref29","doi-asserted-by":"crossref","first-page":"860985","DOI":"10.3389\/fchem.2022.860985","volume":"10","author":"Zheng","year":"2022","journal-title":"Front Chem"},{"issue":"5","key":"10.3346\/jkms.2024.39.e320_ref30","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.eururo.2020.07.002","volume":"78","author":"van Rhijn","year":"2020","journal-title":"Eur Urol"},{"issue":"19","key":"10.3346\/jkms.2024.39.e320_ref31","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.3390\/cancers13194891","volume":"13","author":"Xiao","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.3346\/jkms.2024.39.e320_ref32","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13045-024-01558-1","volume":"17","author":"Zhang","year":"2024","journal-title":"J Hematol Oncol"},{"issue":"3","key":"10.3346\/jkms.2024.39.e320_ref33","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"issue":"4","key":"10.3346\/jkms.2024.39.e320_ref34","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","volume":"72","author":"Seiler","year":"2017","journal-title":"Eur Urol"},{"issue":"6","key":"10.3346\/jkms.2024.39.e320_ref35","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.eururo.2020.07.018","volume":"78","author":"Teo","year":"2020","journal-title":"Eur Urol"},{"issue":"2","key":"10.3346\/jkms.2024.39.e320_ref36","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3233\/BLC-180205","volume":"5","author":"Ibrahim","year":"2019","journal-title":"Bladder Cancer"},{"issue":"5","key":"10.3346\/jkms.2024.39.e320_ref37","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.euf.2018.02.013","volume":"5","author":"Necchi","year":"2019","journal-title":"Eur Urol Focus"},{"issue":"5","key":"10.3346\/jkms.2024.39.e320_ref38","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/bju.13552","volume":"118","author":"Sethakorn","year":"2016","journal-title":"BJU Int"},{"issue":"22","key":"10.3346\/jkms.2024.39.e320_ref39","doi-asserted-by":"crossref","first-page":"5796","DOI":"10.3390\/cancers13225796","volume":"13","author":"Szymczyk","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.3346\/jkms.2024.39.e320_ref40","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/sj.bjc.6606016","volume":"104","author":"Lamont","year":"2011","journal-title":"Br J Cancer"},{"issue":"8","key":"10.3346\/jkms.2024.39.e320_ref41","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1517\/13543784.2013.812630","volume":"22","author":"Rolfo","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"issue":"11","key":"10.3346\/jkms.2024.39.e320_ref42","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.19.01598","volume":"38","author":"Taylor","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.3346\/jkms.2024.39.e320_ref43","doi-asserted-by":"crossref","first-page":"907377","DOI":"10.3389\/fonc.2022.907377","volume":"12","author":"Zheng","year":"2023","journal-title":"Front Oncol"},{"issue":"6","key":"10.3346\/jkms.2024.39.e320_ref44","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3390\/jpm11060571","volume":"11","author":"Subhan","year":"2021","journal-title":"J Pers Med"},{"issue":"3","key":"10.3346\/jkms.2024.39.e320_ref45","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/jcph.1529","volume":"60","author":"Li","year":"2020","journal-title":"J Clin Pharmacol"},{"issue":"16","key":"10.3346\/jkms.2024.39.e320_ref46","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1158\/1078-0432.CCR-18-3334","volume":"25","author":"Bahleda","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.3346\/jkms.2024.39.e320_ref47","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s11864-022-01009-4","volume":"23","author":"Peng","year":"2022","journal-title":"Curr Treat Options Oncol"},{"key":"10.3346\/jkms.2024.39.e320_ref48","unstructured":"Janssen Inc. Product monograph including patient medication information. Updated 2021. Accessed August 21, 2024.  https:\/\/pdf.hres.ca\/dpd_pm\/00063651.PDF"},{"issue":"4","key":"10.3346\/jkms.2024.39.e320_ref49","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"key":"10.3346\/jkms.2024.39.e320_ref50","unstructured":"U.S. Food and Drug Administration (FDA). FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma. Updated 2019. Accessed August 21, 2024.  https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma"},{"issue":"21","key":"10.3346\/jkms.2024.39.e320_ref51","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","volume":"389","author":"Loriot","year":"2023","journal-title":"N Engl J Med"},{"key":"10.3346\/jkms.2024.39.e320_ref52","unstructured":"U.S. Food and Drug Administration (FDA). FDA approves erdafitinib for locally advanced or metastatic urothelial carcinoma. Updated 2019. Accessed August 21, 2024.  https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-erdafitinib-locally-advanced-or-metastatic-urothelial-carcinoma"},{"issue":"6","key":"10.3346\/jkms.2024.39.e320_ref53","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/14737140.2020.1770600","volume":"20","author":"Qin","year":"2020","journal-title":"Expert Rev Anticancer Ther"},{"issue":"9","key":"10.3346\/jkms.2024.39.e320_ref54","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1158\/2326-6066.CIR-18-0595","volume":"7","author":"Palakurthi","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.3346\/jkms.2024.39.e320_ref55","doi-asserted-by":"crossref","first-page":"1258388","DOI":"10.3389\/fimmu.2023.1258388","volume":"14","author":"Benjamin","year":"2023","journal-title":"Front Immunol"},{"issue":"16","key":"10.3346\/jkms.2024.39.e320_ref56","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1200\/JCO.2023.41.16_suppl.4504","volume":"41","author":"Siefker-Radtke","year":"2023","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.3346\/jkms.2024.39.e320_ref57","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1200\/JCO.2021.39.15_suppl.4521","volume":"39","author":"Rosenberg","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.3346\/jkms.2024.39.e320_ref58","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.urolonc.2021.10.003","volume":"40","author":"Zengin","year":"2022","journal-title":"Urol Oncol"},{"issue":"1","key":"10.3346\/jkms.2024.39.e320_ref59","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41571-023-00826-2","volume":"21","author":"Nadal","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.3346\/jkms.2024.39.e320_ref60","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3390\/ijms25020849","volume":"25","author":"Shan","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.3346\/jkms.2024.39.e320_ref61","doi-asserted-by":"crossref","first-page":"5581","DOI":"10.2147\/IJN.S460844","volume":"19","author":"Wang","year":"2024","journal-title":"Int J Nanomedicine"},{"key":"10.3346\/jkms.2024.39.e320_ref62","doi-asserted-by":"crossref","first-page":"1758835919890285","DOI":"10.1177\/1758835919890285","volume":"11","author":"Casadei","year":"2019","journal-title":"Ther Adv Med Oncol"},{"issue":"15","key":"10.3346\/jkms.2024.39.e320_ref63","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1200\/JCO.2019.37.15_suppl.4511","volume":"37","author":"Siefker-Radtke","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.3346\/jkms.2024.39.e320_ref64","doi-asserted-by":"crossref","first-page":"290","DOI":"10.5534\/wjmh.230177","volume":"42","author":"Kwon","year":"2024","journal-title":"World J Mens Health"},{"key":"10.3346\/jkms.2024.39.e320_ref65","doi-asserted-by":"crossref","first-page":"17588359231221337","DOI":"10.1177\/17588359231221337","volume":"16","author":"Bourlon","year":"2024","journal-title":"Ther Adv Med Oncol"},{"issue":"5","key":"10.3346\/jkms.2024.39.e320_ref66","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.3390\/jcm13051305","volume":"13","author":"Yu","year":"2024","journal-title":"J Clin Med"},{"issue":"6","key":"10.3346\/jkms.2024.39.e320_ref67","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2017.05.032","volume":"72","author":"Pietzak","year":"2017","journal-title":"Eur Urol"},{"issue":"2","key":"10.3346\/jkms.2024.39.e320_ref68","doi-asserted-by":"crossref","first-page":"148","DOI":"10.30699\/ijp.14.2.148","volume":"14","author":"Akanksha","year":"2019","journal-title":"Iran J Pathol"},{"issue":"1","key":"10.3346\/jkms.2024.39.e320_ref69","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrc3817","volume":"15","author":"Knowles","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"10.3346\/jkms.2024.39.e320_ref70","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1158\/1078-0432.CCR-18-3147","volume":"25","author":"Nassar","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.3346\/jkms.2024.39.e320_ref71","doi-asserted-by":"crossref","first-page":"25826","DOI":"10.18632\/oncotarget.8404","volume":"7","author":"Yuan","year":"2016","journal-title":"Oncotarget"},{"issue":"16","key":"10.3346\/jkms.2024.39.e320_ref72","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1200\/JCO.2022.40.16_suppl.4568","volume":"40","author":"Bou Zerdan","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.3346\/jkms.2024.39.e320_ref73","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1200\/JCO.2024.42.4_suppl.647","volume":"42","author":"Matsubara","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.3346\/jkms.2024.39.e320_ref74","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1007\/s10147-024-02583-3","volume":"29","author":"Matsubara","year":"2024","journal-title":"Int J Clin Oncol"},{"issue":"4","key":"10.3346\/jkms.2024.39.e320_ref75","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41571-024-00869-z","volume":"21","author":"Katoh","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.3346\/jkms.2024.39.e320_ref76","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-19-2035","volume":"26","author":"Facchinetti","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.3346\/jkms.2024.39.e320_ref77","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.3390\/cells11121901","volume":"11","author":"Vasseur","year":"2022","journal-title":"Cells"},{"issue":"5","key":"10.3346\/jkms.2024.39.e320_ref78","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nrc.2017.8","volume":"17","author":"Babina","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"19","key":"10.3346\/jkms.2024.39.e320_ref79","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.3390\/cells11193180","volume":"11","author":"Ellinghaus","year":"2022","journal-title":"Cells"},{"key":"10.3346\/jkms.2024.39.e320_ref80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.acr.2020.04.002","volume":"147","author":"Ghosh","year":"2020","journal-title":"Adv Cancer Res"},{"issue":"22","key":"10.3346\/jkms.2024.39.e320_ref81","doi-asserted-by":"crossref","first-page":"13509","DOI":"10.1080\/07391102.2023.2191721","volume":"41","author":"Mahapatra","year":"2023","journal-title":"J Biomol Struct Dyn"},{"issue":"5","key":"10.3346\/jkms.2024.39.e320_ref82","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41585-020-0297-9","volume":"17","author":"Maia","year":"2020","journal-title":"Nat Rev Urol"},{"issue":"9","key":"10.3346\/jkms.2024.39.e320_ref83","first-page":"1325","volume":"11","author":"Capuozzo","year":"2022","journal-title":"Biology (Basel)"},{"key":"10.3346\/jkms.2024.39.e320_ref84","doi-asserted-by":"crossref","first-page":"1137510","DOI":"10.3389\/fonc.2023.1137510","volume":"13","author":"Brandi","year":"2023","journal-title":"Front Oncol"},{"issue":"1","key":"10.3346\/jkms.2024.39.e320_ref85","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.annonc.2023.09.3116","volume":"35","author":"Catto","year":"2024","journal-title":"Ann Oncol"},{"issue":"6","key":"10.3346\/jkms.2024.39.e320_ref86","doi-asserted-by":"crossref","first-page":"TPS583","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS583","volume":"41","author":"Vilaseca","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.3346\/jkms.2024.39.e320_ref87","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.7150\/jca.40531","volume":"11","author":"Zhou","year":"2020","journal-title":"J Cancer"},{"issue":"1","key":"10.3346\/jkms.2024.39.e320_ref88","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13045-022-01311-6","volume":"15","author":"Shi","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.3346\/jkms.2024.39.e320_ref89","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2147\/OTT.S318332","volume":"15","author":"Sayegh","year":"2022","journal-title":"Onco Targets Ther"},{"issue":"1","key":"10.3346\/jkms.2024.39.e320_ref90","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.annonc.2023.10.003","volume":"35","author":"Siefker-Radtke","year":"2024","journal-title":"Ann Oncol"},{"issue":"6","key":"10.3346\/jkms.2024.39.e320_ref91","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1200\/JCO.2023.41.6_suppl.503","volume":"41","author":"Catto","year":"2023","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.3346\/jkms.2024.39.e320_ref92","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.2217\/fon-2021-1629","volume":"18","author":"Pal","year":"2022","journal-title":"Future Oncol"},{"key":"10.3346\/jkms.2024.39.e320_ref93","unstructured":"Janssen Research & Development, LLC. A study of erdafitinib versus investigator choice of intravesical chemotherapy in participants who received Bacillus Calmette-Gu\u00e9rin (BCG) and recurred with high risk non-muscle-invasive bladder cancer (NMIBC). Updated 2024. Accessed August 21, 2024.  https:\/\/clinicaltrials.gov\/study\/NCT04172675"},{"key":"10.3346\/jkms.2024.39.e320_ref94","unstructured":"Janssen Research & Development, LLC. Study of erdafitinib intravesical delivery system for localized bladder cancer. Updated 2024. Accessed August 21, 2024.  https:\/\/clinicaltrials.gov\/study\/NCT05316155"},{"key":"10.3346\/jkms.2024.39.e320_ref95","unstructured":"National Cancer Institute (US). Testing combination erdafitinib and enfortumab vedotin in metastatic bladder cancer after treatment with chemotherapy and immunotherapy. Updated 2024. Accessed August 21, 2024.  https:\/\/clinicaltrials.gov\/study\/NCT04963153."},{"key":"10.3346\/jkms.2024.39.e320_ref96","unstructured":"Tyra Biosciences, Inc. Safety and preliminary anti-tumor activity of TYRA-300 in advanced urothelial carcinoma and other solid tumors with FGFR3 gene alterations (SURF301). Updated 2024. Accessed August 21, 2024.  https:\/\/clinicaltrials.gov\/study\/NCT05544552."},{"key":"10.3346\/jkms.2024.39.e320_ref97","unstructured":"Bayer. Phase 1b\/2 study of rogaratinib (BAY1163877) in combination with atezolizumab in urothelial carcinoma (FORT-2). Updated 2024. Accessed August 21, 2024.  https:\/\/clinicaltrials.gov\/study\/NCT03473756."},{"key":"10.3346\/jkms.2024.39.e320_ref98","unstructured":"Abbisko Therapeutics Co, Ltd. A study to evaluate the safety and efficacy of AZD4547 combination with tislelizumab in patients with mUC. Updated 2023. Accessed August 21, 2024.  https:\/\/clinicaltrials.gov\/study\/NCT05775874."},{"key":"10.3346\/jkms.2024.39.e320_ref99","unstructured":"Eigl B. A study to compare the results of FGFR testing by either ctDNA blood testing or standard tumor tissue testing. Updated 2024. Accessed August 21, 2024.  https:\/\/clinicaltrials.gov\/study\/NCT06129084"},{"key":"10.3346\/jkms.2024.39.e320_ref100","unstructured":"Taiho Oncology, Inc. Futibatinib and pembrolizumab combination in the treatment of advanced or metastatic urothelial carcinoma. Updated 2024. Accessed August 21, 2024.  https:\/\/clinicaltrials.gov\/study\/NCT04601857"},{"key":"10.3346\/jkms.2024.39.e320_ref101","unstructured":"Kinnate Biopharma. A study to evaluate KIN-3248 in participants with advanced tumors harboring FGFR2 and\/\/or FGFR3 gene alterations. Updated 2024. Accessed August 21, 2024.  https:\/\/clinicaltrials.gov\/study\/NCT05242822"},{"key":"10.3346\/jkms.2024.39.e320_ref102","unstructured":"Beijing InnoCare Pharma Tech Co., Ltd. A study of ICP-192 in patients with advanced solid tumors. Updated 2023. Accessed August 21, 2024.  https:\/\/clinicaltrials.gov\/study\/NCT04565275"},{"key":"10.3346\/jkms.2024.39.e320_ref103","unstructured":"Janssen Research & Development, LLC. A study of erdafitinib in participants with metastatic or locally advanced urothelial cancer. Updated 2024. Accessed August 21, 2024.  https:\/\/clinicaltrials.gov\/study\/NCT03473743"},{"key":"10.3346\/jkms.2024.39.e320_ref104","unstructured":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. A study of pemigatinib in non-muscle invasive bladder cancer patients with recurrent low- or intermediate-risk tumors. Updated 2024. Accessed August 21, 2024.  https:\/\/clinicaltrials.gov\/study\/NCT03914794"},{"key":"10.3346\/jkms.2024.39.e320_ref105","unstructured":"Eli Lilly and Company. A study of LOXO-435 in participants with cancer with a change in a gene called FGFR3. Updated 2024. Accessed August 21, 2024.  https:\/\/clinicaltrials.gov\/study\/NCT05614739"}],"container-title":["Journal of Korean Medical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jkms.org\/pdf\/10.3346\/jkms.2024.39.e320","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jkms.org\/DOIx.php?id=10.3346\/jkms.2024.39.e320","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jkms.org\/DOIx.php?id=10.3346\/jkms.2024.39.e320","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T06:07:22Z","timestamp":1731478042000},"score":1,"resource":{"primary":{"URL":"https:\/\/jkms.org\/DOIx.php?id=10.3346\/jkms.2024.39.e320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":105,"journal-issue":{"issue":"43","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.3346\/jkms.2024.39.e320","relation":{},"ISSN":["1011-8934","1598-6357"],"issn-type":[{"value":"1011-8934","type":"print"},{"value":"1598-6357","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"2024-05-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-21","name":"published_online","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"\u00a9 2024 The Korean Academy of Medical Sciences.","name":"copyright","label":"Copyright","group":{"name":"Copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.","name":"license","label":"License","explanation":{"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},"group":{"name":"Copyright_and_licensing","label":"Copyright and Licensing"}}],"article-number":"e320"}}